Daxor (DXR) Competitors

Daxor logo
$8.10 -0.25 (-2.99%)
Closing price 03:49 PM Eastern
Extended Trading
$8.07 -0.03 (-0.31%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

DXR vs. KRMD, INGN, TLSI, LUNG, and FOCL

Should you buy Daxor stock or one of its competitors? Daxor's main competitors and comparable companies include KORU Medical Systems (KRMD), Inogen (INGN), TriSalus Life Sciences (TLSI), Pulmonx (LUNG), and FocalTherics (FOCL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Daxor compare to KORU Medical Systems?

KORU Medical Systems (NASDAQ:KRMD) and Daxor (NASDAQ:DXR) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, media sentiment, risk, analyst recommendations, earnings and institutional ownership.

Daxor has a net margin of 0.00% compared to KORU Medical Systems' net margin of -1.78%. Daxor's return on equity of 0.00% beat KORU Medical Systems' return on equity.

Company Net Margins Return on Equity Return on Assets
KORU Medical Systems-1.78% -4.62% -2.90%
Daxor N/A N/A N/A

58.6% of KORU Medical Systems shares are held by institutional investors. Comparatively, 1.3% of Daxor shares are held by institutional investors. 18.5% of KORU Medical Systems shares are held by insiders. Comparatively, 51.5% of Daxor shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Daxor has lower revenue, but higher earnings than KORU Medical Systems.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
KORU Medical Systems$41.13M3.89-$2.64M-$0.02N/A
DaxorN/AN/AN/AN/AN/A

KORU Medical Systems has a beta of 0.47, indicating that its stock price is 53% less volatile than the broader market. Comparatively, Daxor has a beta of 0.43, indicating that its stock price is 57% less volatile than the broader market.

KORU Medical Systems presently has a consensus price target of $6.50, suggesting a potential upside of 76.15%. Given KORU Medical Systems' higher probable upside, analysts plainly believe KORU Medical Systems is more favorable than Daxor.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
KORU Medical Systems
1 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.43
Daxor
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50

In the previous week, KORU Medical Systems had 10 more articles in the media than Daxor. MarketBeat recorded 12 mentions for KORU Medical Systems and 2 mentions for Daxor. Daxor's average media sentiment score of 1.39 beat KORU Medical Systems' score of 0.65 indicating that Daxor is being referred to more favorably in the news media.

Company Overall Sentiment
KORU Medical Systems Positive
Daxor Positive

Summary

KORU Medical Systems and Daxor tied by winning 6 of the 12 factors compared between the two stocks.

How does Daxor compare to Inogen?

Inogen (NASDAQ:INGN) and Daxor (NASDAQ:DXR) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends, earnings and media sentiment.

In the previous week, Inogen and Inogen both had 2 articles in the media. Daxor's average media sentiment score of 1.39 beat Inogen's score of 0.74 indicating that Daxor is being referred to more favorably in the news media.

Company Overall Sentiment
Inogen Positive
Daxor Positive

Daxor has a net margin of 0.00% compared to Inogen's net margin of -10.46%. Daxor's return on equity of 0.00% beat Inogen's return on equity.

Company Net Margins Return on Equity Return on Assets
Inogen-10.46% -19.29% -12.02%
Daxor N/A N/A N/A

Daxor has lower revenue, but higher earnings than Inogen.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Inogen$348.67M0.42-$22.75M-$1.31N/A
DaxorN/AN/AN/AN/AN/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Inogen
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
2.50
Daxor
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50

89.9% of Inogen shares are owned by institutional investors. Comparatively, 1.3% of Daxor shares are owned by institutional investors. 2.5% of Inogen shares are owned by company insiders. Comparatively, 51.5% of Daxor shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Inogen has a beta of 1.51, indicating that its share price is 51% more volatile than the broader market. Comparatively, Daxor has a beta of 0.43, indicating that its share price is 57% less volatile than the broader market.

Summary

Daxor beats Inogen on 6 of the 10 factors compared between the two stocks.

How does Daxor compare to TriSalus Life Sciences?

TriSalus Life Sciences (NASDAQ:TLSI) and Daxor (NASDAQ:DXR) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and media sentiment.

2.6% of TriSalus Life Sciences shares are held by institutional investors. Comparatively, 1.3% of Daxor shares are held by institutional investors. 16.3% of TriSalus Life Sciences shares are held by company insiders. Comparatively, 51.5% of Daxor shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

TriSalus Life Sciences currently has a consensus price target of $9.20, suggesting a potential upside of 305.29%. Given TriSalus Life Sciences' higher possible upside, research analysts plainly believe TriSalus Life Sciences is more favorable than Daxor.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TriSalus Life Sciences
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50
Daxor
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50

In the previous week, TriSalus Life Sciences had 25 more articles in the media than Daxor. MarketBeat recorded 27 mentions for TriSalus Life Sciences and 2 mentions for Daxor. Daxor's average media sentiment score of 1.39 beat TriSalus Life Sciences' score of -0.02 indicating that Daxor is being referred to more favorably in the news media.

Company Overall Sentiment
TriSalus Life Sciences Neutral
Daxor Positive

Daxor has a net margin of 0.00% compared to TriSalus Life Sciences' net margin of -56.60%.

Company Net Margins Return on Equity Return on Assets
TriSalus Life Sciences-56.60% N/A -55.00%
Daxor N/A N/A N/A

Daxor has lower revenue, but higher earnings than TriSalus Life Sciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TriSalus Life Sciences$45.15M3.10-$39.23M-$0.49N/A
DaxorN/AN/AN/AN/AN/A

TriSalus Life Sciences has a beta of 0.5, meaning that its stock price is 50% less volatile than the broader market. Comparatively, Daxor has a beta of 0.43, meaning that its stock price is 57% less volatile than the broader market.

Summary

TriSalus Life Sciences beats Daxor on 6 of the 10 factors compared between the two stocks.

How does Daxor compare to Pulmonx?

Pulmonx (NASDAQ:LUNG) and Daxor (NASDAQ:DXR) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends, valuation and media sentiment.

Daxor has a net margin of 0.00% compared to Pulmonx's net margin of -47.93%. Daxor's return on equity of 0.00% beat Pulmonx's return on equity.

Company Net Margins Return on Equity Return on Assets
Pulmonx-47.93% -98.23% -35.89%
Daxor N/A N/A N/A

Pulmonx has a beta of 0.19, suggesting that its stock price is 81% less volatile than the broader market. Comparatively, Daxor has a beta of 0.43, suggesting that its stock price is 57% less volatile than the broader market.

91.0% of Pulmonx shares are owned by institutional investors. Comparatively, 1.3% of Daxor shares are owned by institutional investors. 7.5% of Pulmonx shares are owned by company insiders. Comparatively, 51.5% of Daxor shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Pulmonx presently has a consensus target price of $7.67, suggesting a potential upside of 173.81%. Given Pulmonx's higher probable upside, equities analysts plainly believe Pulmonx is more favorable than Daxor.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pulmonx
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
Daxor
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50

Daxor has lower revenue, but higher earnings than Pulmonx.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pulmonx$90.50M1.35-$54M-$1.01N/A
DaxorN/AN/AN/AN/AN/A

In the previous week, Daxor had 1 more articles in the media than Pulmonx. MarketBeat recorded 2 mentions for Daxor and 1 mentions for Pulmonx. Pulmonx's average media sentiment score of 1.82 beat Daxor's score of 1.39 indicating that Pulmonx is being referred to more favorably in the media.

Company Overall Sentiment
Pulmonx Very Positive
Daxor Positive

Summary

Daxor beats Pulmonx on 6 of the 11 factors compared between the two stocks.

How does Daxor compare to FocalTherics?

Daxor (NASDAQ:DXR) and FocalTherics (NASDAQ:FOCL) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and media sentiment.

Daxor has a beta of 0.43, indicating that its share price is 57% less volatile than the broader market. Comparatively, FocalTherics has a beta of -0.02, indicating that its share price is 102% less volatile than the broader market.

FocalTherics has a consensus price target of $9.67, indicating a potential upside of 204.94%. Given FocalTherics' higher possible upside, analysts plainly believe FocalTherics is more favorable than Daxor.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Daxor
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50
FocalTherics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.50

1.3% of Daxor shares are owned by institutional investors. Comparatively, 62.7% of FocalTherics shares are owned by institutional investors. 51.5% of Daxor shares are owned by company insiders. Comparatively, 10.1% of FocalTherics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, FocalTherics had 11 more articles in the media than Daxor. MarketBeat recorded 13 mentions for FocalTherics and 2 mentions for Daxor. Daxor's average media sentiment score of 1.39 beat FocalTherics' score of 0.66 indicating that Daxor is being referred to more favorably in the media.

Company Overall Sentiment
Daxor Positive
FocalTherics Positive

Daxor has higher earnings, but lower revenue than FocalTherics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DaxorN/AN/AN/AN/AN/A
FocalTherics$70.53M1.69-$29.25M-$0.98N/A

Daxor has a net margin of 0.00% compared to FocalTherics' net margin of -59.77%. Daxor's return on equity of 0.00% beat FocalTherics' return on equity.

Company Net Margins Return on Equity Return on Assets
DaxorN/A N/A N/A
FocalTherics -59.77%-223.32%-41.32%

Summary

Daxor beats FocalTherics on 6 of the 11 factors compared between the two stocks.

Get Daxor News Delivered to You Automatically

Sign up to receive the latest news and ratings for DXR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DXR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DXR vs. The Competition

MetricDaxorHealthcare Equipment & Supplies IndustryHealthcare SectorNASDAQ Exchange
Market Cap$48.78M$5.98B$7.82B$11.74B
Dividend YieldN/A1.68%2.47%4.47%
P/E RatioN/A35.3532.7626.82
Price / SalesN/A5.398.565.70
Price / CashN/A23.6221.0121.90
Price / BookN/A4.174.463.72
Net IncomeN/A$143.92M$3.52B$393.10M
7 Day Performance-4.82%-5.00%-5.47%-4.73%
1 Month Performance-19.37%-3.68%-4.57%-7.14%
1 Year Performance-37.40%-0.46%-1.79%-7.51%

Daxor Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DXR
Daxor
1.878 of 5 stars
$8.10
-3.0%
N/A-36.2%$48.78MN/AN/A37
KRMD
KORU Medical Systems
3.8552 of 5 stars
$3.72
+0.7%
$6.50
+75.0%
-14.6%$160.94M$41.13MN/A73
INGN
Inogen
1.0796 of 5 stars
$5.63
+0.1%
N/A-18.4%$145.86M$348.67MN/A753
TLSI
TriSalus Life Sciences
2.9846 of 5 stars
$2.28
-9.7%
$9.20
+304.4%
-50.2%$140.77M$45.15MN/A102
LUNG
Pulmonx
2.8349 of 5 stars
$2.89
-3.6%
$7.67
+165.2%
+87.9%$124.38M$90.50MN/A296

Related Companies and Tools


This page (NASDAQ:DXR) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners